Sustainable Use of a Real-Time Continuous Glucose Monitoring System from 2018 to 2020
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
We aimed to describe patterns of continuous glucose monitoring (CGM) system use and glycemic outcomes from 2018 to 2020 in a large real-world cohort by analyzing anonymized data from US-based CGM users who transitioned from the G5 to the G6 System (Dexcom) in 2018. The main end points were persistent use, within-day and between-day utilization, hypoglycemia, time in range (TIR, 70–180 mg/dL [3.9–10 mmol/L]), and use of the optional calibration feature in 2019 and 2020. In a cohort of 31,034 individuals, rates of persistent use were high, with 27,932 (90.0%) and 26,861 (86.6%) continuing to upload data in 2019 and 2020, respectively. Compared with G5 use, G6 use was associated with higher device utilization, less hypoglycemia, higher TIR (in 2020), and >80% fewer calibrations in both 2019 and 2020 ( P' s < 0.001). High persistence and utilization of the G6 system may contribute to sustainable glycemic outcomes and decreased user burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“The mean fraction of glucose values that were 70 or 54mg/dL was consistently lower than the current international consensus goals for most people with diabetes 11 but was significantly lower during G6 use than during G5 use.”
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030 · cited 1×
“3,4 The features they provide, such as trends and alarms for hypoglycemia and hyperglycemia, are also associated with A1C reduction and improved time with glucose values in the 70–180 mg/dL range (TIR), even in the absence of AID systems.”
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Šoupal, J., Petruželková, L., Grunberger, G., Hásková, A., Flekač, M., Matoulek, M., Mikeš, O., Pelcl, T., Škrha, J., Horová, E., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0888 · Cited by 242 · cited 3×
“…observations from the COMISAIR study, where participants who self-selected to use CGM for glucose monitoring had lower A1C values than those who used SMBG, 7 and the SILVER study that reported on the long-term effects of CGM use on A1C reduction, treatment satisfaction, and hypoglycemic confi-dence.”
Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology
Pinsker, J. E., Müller, L., Constantin, A., Leas, S., Manning, M., McElwee Malloy, M., Singh, H., & Habif, S. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0388 · Cited by 147 · cited 1×
“3,4 The features they provide, such as trends and alarms for hypoglycemia and hyperglycemia, are also associated with A1C reduction and improved time with glucose values in the 70–180 mg/dL range (TIR), even in the absence of AID systems.”
Improved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts
Abraham, S. B., Arunachalam, S., Zhong, A., Agrawal, P., Cohen, O., & McMahon, C. M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819859334 · Cited by 63 · cited 1×
“5,6 Long-term prospective studies have associated sustained glycemic 7 and psychosocial 7,8 benefits with persistent CGM use, regardless of the method of insulin delivery.”
Youth Involvement in the Decision to Start CGM Predicts Subsequent CGM Use
Miller, V. A., Xiao, R., Slick, N., Feudtner, C., & Willi, S. M. (2020) · Diabetes Care · doi:10.2337/dc20-0348 · Cited by 23
Cited by
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Elbalshy, M., Haszard, J., Smith, H., Kuroko, S., Galland, B., Oliver, N., Shah, V., de Bock, M. I., & Wheeler, B. J. (2022) · Diabetic Medicine · doi:10.1111/dme.14854 · Cited by 104
Miller, K. M., Kanapka, L. G., Rickels, M. R., Ahmann, A. J., Aleppo, G., Ang, L., Bhargava, A., Bode, B. W., Carlson, A., Chaytor, N. S., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0503 · Cited by 73
Acciaroli, G., van der Linden, J., Chao, C., Walker, T. C., & Oliver, N. (2023) · Diabetic Medicine · doi:10.1111/dme.14946 · Cited by 4
Self-citation
Metadata
- Authors
- van der Linden, J., Welsh, J. B., & Walker, T. C.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2021-07-01
- Volume
- 23
- Issue
- 7
- Pages
- 508-511
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W3128855515
- Cited by
- 19
- References
- 8
- FWCI
- 2.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sustainable Use of a Real-Time Continuous Glucose Monitoring System from 2018 to 2020. https://app.cochat.ai/papers/10.1089/dia.2021.0014
- The paper
- van der Linden, J., Welsh, J. B., & Walker, T. C. (2021). Sustainable Use of a Real-Time Continuous Glucose Monitoring System from 2018 to 2020. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2021.0014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.